vs
アッヴィ（ABBV）とCooper Companies (The)（COO）の財務データ比較。上の社名をクリックして会社を切り替えられます
アッヴィの直近四半期売上が大きい（$16.6B vs $1.1B、Cooper Companies (The)の約15.6倍）。アッヴィの純利益率が高く（10.9% vs 7.9%、差は3.0%）。アッヴィの前年同期比売上増加率が高い（10.0% vs 4.6%）。アッヴィの直近四半期フリーキャッシュフローが多い（$4.9B vs $149.9M）。過去8四半期でアッヴィの売上複合成長率が高い（16.2% vs 6.9%）
アッヴィは米国イリノイ州ノースシカゴに本社を置く製薬会社で、多様な疾患領域に対応する治療薬の開発・製造を行っており、世界中の患者に質の高い治療選択肢を提供することを事業の軸としています。
クーパーカンパニーズ（CooperCompanies）は米国カリフォルニア州サンラモンに本社を置く世界的な医療機器企業です。コンタクトレンズを製造するクーパービジョンと、女性医療向けの医療機器、生殖・ゲノム製品を扱うクーパーサージカルの2つの事業部を展開しています。
ABBV vs COO — 直接比較
売上が大きい
ABBV
15.6倍大きい
$1.1B
売上成長率が高い
ABBV
+5.5%の差
4.6%
純利益率が高い
ABBV
純利益率が3.0%高い
7.9%
フリーキャッシュフローが多い
ABBV
FCF $4.7B多い
$149.9M
2年売上CAGRが高い
ABBV
2年複合成長率
6.9%
損益計算書 — Q4 2025 vs Q4 2025
| 指標 | | |
|---|---|---|
| 売上 | $16.6B | $1.1B |
| 純利益 | $1.8B | $84.6M |
| 粗利率 | 72.6% | 61.1% |
| 営業利益率 | 27.3% | 13.2% |
| 純利益率 | 10.9% | 7.9% |
| 売上前年比 | 10.0% | 4.6% |
| 純利益前年比 | 8354.5% | -28.0% |
| EPS（希薄化後） | $1.02 | $0.42 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上ABBVCOO
| Q4 25 | $16.6B | $1.1B | ||
| Q3 25 | $15.8B | $1.1B | ||
| Q2 25 | $15.4B | $1.0B | ||
| Q1 25 | $13.3B | $964.7M | ||
| Q4 24 | $15.1B | $1.0B | ||
| Q3 24 | $14.5B | $1.0B | ||
| Q2 24 | $14.5B | $942.6M | ||
| Q1 24 | $12.3B | $931.6M |
純利益ABBVCOO
| Q4 25 | $1.8B | $84.6M | ||
| Q3 25 | $186.0M | $98.3M | ||
| Q2 25 | $938.0M | $87.7M | ||
| Q1 25 | $1.3B | $104.3M | ||
| Q4 24 | $-22.0M | $117.5M | ||
| Q3 24 | $1.6B | $104.7M | ||
| Q2 24 | $1.4B | $88.9M | ||
| Q1 24 | $1.4B | $81.2M |
粗利率ABBVCOO
| Q4 25 | 72.6% | 61.1% | ||
| Q3 25 | 66.4% | 65.3% | ||
| Q2 25 | 71.8% | 67.8% | ||
| Q1 25 | 70.0% | 68.4% | ||
| Q4 24 | 70.9% | 66.5% | ||
| Q3 24 | 70.9% | 66.1% | ||
| Q2 24 | 70.9% | 67.0% | ||
| Q1 24 | 66.7% | 67.0% |
営業利益率ABBVCOO
| Q4 25 | 27.3% | 13.2% | ||
| Q3 25 | 12.1% | 16.6% | ||
| Q2 25 | 31.7% | 18.4% | ||
| Q1 25 | 28.0% | 18.9% | ||
| Q4 24 | -9.9% | 19.5% | ||
| Q3 24 | 26.5% | 19.2% | ||
| Q2 24 | 27.6% | 17.2% | ||
| Q1 24 | 22.7% | 16.4% |
純利益率ABBVCOO
| Q4 25 | 10.9% | 7.9% | ||
| Q3 25 | 1.2% | 9.3% | ||
| Q2 25 | 6.1% | 8.7% | ||
| Q1 25 | 9.6% | 10.8% | ||
| Q4 24 | -0.1% | 11.5% | ||
| Q3 24 | 10.8% | 10.4% | ||
| Q2 24 | 9.5% | 9.4% | ||
| Q1 24 | 11.1% | 8.7% |
EPS（希薄化後）ABBVCOO
| Q4 25 | $1.02 | $0.42 | ||
| Q3 25 | $0.10 | $0.49 | ||
| Q2 25 | $0.52 | $0.44 | ||
| Q1 25 | $0.72 | $0.52 | ||
| Q4 24 | $-0.03 | $0.59 | ||
| Q3 24 | $0.88 | $0.52 | ||
| Q2 24 | $0.77 | $0.44 | ||
| Q1 24 | $0.77 | $0.41 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $5.3B | $110.6M |
| 総負債低いほど良い | $58.9B | $2.5B |
| 株主資本純資産 | $-3.3B | $8.2B |
| 総資産 | $134.0B | $12.4B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.30× |
8四半期トレンド — 暦四半期で整列
現金・短期投資ABBVCOO
| Q4 25 | $5.3B | $110.6M | ||
| Q3 25 | $5.7B | $124.9M | ||
| Q2 25 | $6.5B | $116.2M | ||
| Q1 25 | $5.2B | $100.9M | ||
| Q4 24 | $5.6B | $107.6M | ||
| Q3 24 | $7.3B | $109.7M | ||
| Q2 24 | $13.2B | $112.4M | ||
| Q1 24 | $18.1B | $135.2M |
総負債ABBVCOO
| Q4 25 | $58.9B | $2.5B | ||
| Q3 25 | $63.0B | $2.4B | ||
| Q2 25 | $63.0B | $2.5B | ||
| Q1 25 | $64.5B | $2.5B | ||
| Q4 24 | $60.3B | $2.6B | ||
| Q3 24 | $58.5B | $2.6B | ||
| Q2 24 | $58.0B | $2.7B | ||
| Q1 24 | $63.8B | $2.7B |
株主資本ABBVCOO
| Q4 25 | $-3.3B | $8.2B | ||
| Q3 25 | $-2.6B | $8.4B | ||
| Q2 25 | $-183.0M | $8.3B | ||
| Q1 25 | $1.4B | $8.1B | ||
| Q4 24 | $3.3B | $8.1B | ||
| Q3 24 | $6.0B | $7.9B | ||
| Q2 24 | $6.8B | $7.8B | ||
| Q1 24 | $8.0B | $7.7B |
総資産ABBVCOO
| Q4 25 | $134.0B | $12.4B | ||
| Q3 25 | $133.9B | $12.4B | ||
| Q2 25 | $137.2B | $12.4B | ||
| Q1 25 | $136.2B | $12.2B | ||
| Q4 24 | $135.2B | $12.3B | ||
| Q3 24 | $143.4B | $12.1B | ||
| Q2 24 | $141.9B | $12.0B | ||
| Q1 24 | $148.9B | $12.0B |
負債/資本比率ABBVCOO
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.30× | ||
| Q1 25 | 45.44× | 0.31× | ||
| Q4 24 | 18.15× | 0.32× | ||
| Q3 24 | 9.70× | 0.33× | ||
| Q2 24 | 8.56× | 0.34× | ||
| Q1 24 | 7.97× | 0.35× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $5.2B | $247.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $4.9B | $149.9M |
| FCFマージンFCF / 売上 | 29.4% | 14.1% |
| 設備投資強度設備投資 / 売上 | 2.0% | 9.2% |
| キャッシュ転換率営業CF / 純利益 | 2.87× | 2.93× |
| 直近12ヶ月FCF直近4四半期 | $17.8B | $433.7M |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローABBVCOO
| Q4 25 | $5.2B | $247.9M | ||
| Q3 25 | $7.0B | $261.4M | ||
| Q2 25 | $5.2B | $96.2M | ||
| Q1 25 | $1.6B | $190.6M | ||
| Q4 24 | $7.0B | $268.1M | ||
| Q3 24 | $5.4B | $207.5M | ||
| Q2 24 | $2.3B | $111.0M | ||
| Q1 24 | $4.0B | $122.7M |
フリーキャッシュフローABBVCOO
| Q4 25 | $4.9B | $149.9M | ||
| Q3 25 | $6.6B | $164.5M | ||
| Q2 25 | $4.9B | $18.1M | ||
| Q1 25 | $1.4B | $101.2M | ||
| Q4 24 | $6.8B | $128.1M | ||
| Q3 24 | $5.2B | $118.5M | ||
| Q2 24 | $2.0B | $36.9M | ||
| Q1 24 | $3.8B | $4.6M |
FCFマージンABBVCOO
| Q4 25 | 29.4% | 14.1% | ||
| Q3 25 | 42.1% | 15.5% | ||
| Q2 25 | 31.7% | 1.8% | ||
| Q1 25 | 10.5% | 10.5% | ||
| Q4 24 | 44.7% | 12.6% | ||
| Q3 24 | 35.9% | 11.8% | ||
| Q2 24 | 14.0% | 3.9% | ||
| Q1 24 | 31.3% | 0.5% |
設備投資強度ABBVCOO
| Q4 25 | 2.0% | 9.2% | ||
| Q3 25 | 2.4% | 9.1% | ||
| Q2 25 | 1.7% | 7.8% | ||
| Q1 25 | 1.8% | 9.3% | ||
| Q4 24 | 1.9% | 13.7% | ||
| Q3 24 | 1.7% | 8.9% | ||
| Q2 24 | 1.7% | 7.9% | ||
| Q1 24 | 1.6% | 12.7% |
キャッシュ転換率ABBVCOO
| Q4 25 | 2.87× | 2.93× | ||
| Q3 25 | 37.76× | 2.66× | ||
| Q2 25 | 5.49× | 1.10× | ||
| Q1 25 | 1.27× | 1.83× | ||
| Q4 24 | — | 2.28× | ||
| Q3 24 | 3.49× | 1.98× | ||
| Q2 24 | 1.66× | 1.25× | ||
| Q1 24 | 2.95× | 1.51× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ABBV
セグメントデータなし
COO
| Sphere Other | $365.0M | 34% |
| Toric And Multifocal | $344.7M | 32% |
| Office And Surgical | $214.5M | 20% |
| Fertility | $140.9M | 13% |
